Clinical Trial Update: The PEARL 8.0 Post-Approval Study

View source ↗

Summary

The PEARL 8.0 post-approval trial for Class IV angina sponsored by Cardiogenesis (CryoLife) was terminated; results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angina Pectoris

Snippet

Sponsor: Cardiogenesis Corporation, a wholly-owned subsidiary of CryoLife, Inc. | Conditions: Class IV Angina | Status: TERMINATED | Results posted: 2015-09-30